Viridian Therapeutics Overview
- Year Founded
-
2006
- Status
-
Public
- Employees
-
143
- Stock Symbol
-
VRDN
- Investments
-
2
- Share Price
-
$16.04
- (As of Monday Closing)
Viridian Therapeutics General Information
Description
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
Contact Information
Website
www.viridiantherapeutics.comCorporate Office
- 221 Crescent Street
- Suite 103A
- Waltham, MA 02453
- United States
Corporate Office
- 221 Crescent Street
- Suite 103A
- Waltham, MA 02453
- United States
Viridian Therapeutics Stock Performance
As of 17-Mar-2025, Viridian Therapeutics’s stock price is $16.04. Its current market cap is $1.31B with 81.5M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $16.04 | $15.92 | $11.40 - $27.20 | $1.31B | 81.5M | 1.14M | -$3.07 |
Viridian Therapeutics Financials Summary
As of 31-Dec-2024, Viridian Therapeutics has a trailing 12-month revenue of $302K.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 975,265 | 975,265 | 988,050 | 891,653 |
| Revenue | 302 | 302 | 314 | 1,772 |
| EBITDA | (298,495) | (298,495) | (253,928) | (134,004) |
| Net Income | (269,949) | (269,949) | (237,734) | (129,874) |
| Total Assets | 742,403 | 742,403 | 490,424 | 435,091 |
| Total Debt | 21,095 | 21,095 | 21,048 | 5,258 |
Viridian Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Viridian Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Viridian Therapeutics Comparisons
Industry
Financing
Details
Viridian Therapeutics Competitors (18)
One of Viridian Therapeutics’s 18 competitors is Regulus Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Regulus Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | ||||
| Exonate | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Arrowhead Pharmaceuticals | Corporation | Pasadena, CA | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA |
Viridian Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Viridian Therapeutics Patents
Viridian Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023205915-A1 | Compositions and methods for treatment of thyroid eye disease | Pending | 07-Jan-2022 | ||
| AU-2023205789-A1 | Compositions and methods for treatment of thyroid eye disease | Pending | 07-Jan-2022 | ||
| CA-3242661-A1 | Compositions and methods for treatment of thyroid eye disease | Pending | 07-Jan-2022 | ||
| US-20240343814-A1 | Compositions and methods for treatment of thyroid eye disease | Pending | 07-Jan-2022 | ||
| EP-4460524-A2 | Compositions and methods for treatment of thyroid eye disease | Pending | 07-Jan-2022 | C07K16/2863 |
Viridian Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Viridian Therapeutics Acquisitions (2)
Viridian Therapeutics’s most recent deal was a Merger/Acquisition with Viridian Therapeutics (Biotechnology) for . The deal was made on 27-Oct-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Viridian Therapeutics (Biotechnology) | 27-Oct-2020 | Merger/Acquisition | Biotechnology | ||
| Signal Genetics | 13-Feb-2017 | Merger/Acquisition | Biotechnology |
Viridian Therapeutics ESG
Risk Overview
Risk Rating
Updated February, 14, 2025
35.28 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,946
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Biotechnology
Subindustry
of 366
Rank
Percentile
Viridian Therapeutics FAQs
-
When was Viridian Therapeutics founded?
Viridian Therapeutics was founded in 2006.
-
Where is Viridian Therapeutics headquartered?
Viridian Therapeutics is headquartered in Waltham, MA.
-
What is the size of Viridian Therapeutics?
Viridian Therapeutics has 143 total employees.
-
What industry is Viridian Therapeutics in?
Viridian Therapeutics’s primary industry is Biotechnology.
-
Is Viridian Therapeutics a private or public company?
Viridian Therapeutics is a Public company.
-
What is Viridian Therapeutics’s stock symbol?
The ticker symbol for Viridian Therapeutics is VRDN.
-
What is the current stock price of Viridian Therapeutics?
As of 17-Mar-2025 the stock price of Viridian Therapeutics is $16.04.
-
What is the current market cap of Viridian Therapeutics?
The current market capitalization of Viridian Therapeutics is $1.31B.
-
What is Viridian Therapeutics’s current revenue?
The trailing twelve month revenue for Viridian Therapeutics is $302K.
-
Who are Viridian Therapeutics’s competitors?
Regulus Therapeutics, Dicerna Pharmaceuticals, Exonate, Arrowhead Pharmaceuticals, and Genentech are some of the 18 competitors of Viridian Therapeutics.
-
What is Viridian Therapeutics’s annual earnings per share (EPS)?
Viridian Therapeutics’s EPS for 12 months was -$3.07.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
